Brief: Optimi Health Corp - Trial Initiation Planned For H1 2027, Dosing To Complete By End Of 2027
10/09/2026 13:53
BRIEF-Optimi Health Corp - Trial Initiation Planned For H1 2027, Dosing To Complete By End Of 2027 Sept 10 (Reuters) - Optimi Health Corp OPTI.CD:
OPTIMI HEALTH TO INITIATE PHASE 2 CLINICAL TRIAL EVALUATING PSILOCYBIN-ASSISTED THERAPY FOR MAJOR DEPRESSIVE DISORDER
OPTIMI HEALTH CORP - TRIAL INITIATION PLANNED FOR H1 2027, DOSING TO COMPLETE BY END OF 2027
Source text: ID:nGNX7MFbFw
Further company coverage: OPTI.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Optimi Health
See all newsExplainer: As Trump backs psychedelics research, FDA weighs safety and access standards
Brief: Optimi Health Corp - Trial Initiation Planned For H1 2027, Dosing To Complete By End Of 2027
Brief: Optimi Health Offers 2.4 MLn Common Shares At A Public Offering Price Of US$6.25 Per Share
Brief: Optimi Health Corp Now Sees IPO Of 2.4 Million Common Shares
Trump's psychedelic drug order boosts investor interest with promise of faster reviews